Provectus Biopharmaceuticals, Inc.
PVCT · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -79.4% | 1,844.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | 99.2% | -36.6% | 96.8% |
| R&D Expenses | $0 | $1 | $0 | $1 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $1 | $2 | $1 | $2 |
| Operating Income | $0 | -$2 | -$1 | -$2 |
| % Margin | – | -3,132.8% | -394.1% | -16,289% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$2 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$2 | -$1 | -$2 |
| % Margin | – | -3,222.1% | -409.1% | -16,724.1% |
| EPS | -0.003 | -0.004 | -0.003 | -0.006 |
| % Growth | 27.9% | -59.3% | 52.6% | – |
| EPS Diluted | -0.003 | -0.004 | -0.003 | -0.006 |
| Weighted Avg Shares Out | 420 | 420 | 420 | 420 |
| Weighted Avg Shares Out Dil | 420 | 420 | 420 | 420 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$1 | -$2 | -$1 | -$2 |
| % Margin | – | -3,132% | -393.7% | -16,285.7% |